Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P A Meredith

Showing results (11-20 of 206) with videos related to

Pageof 21
Sort By:
Heart (British Cardiac Society)|August 24, 2000
ACE inhibition and AT(1) receptor blockers: efficacy and duration in hypertensionP A Meredith
BMJ (Clinical Research Ed.)|December 5, 1992
Patient complianceP A Meredith
American Journal of Hypertension|October 1, 1995
Organ protection and optimal blood pressure controlP A Meredith
Archives Des Maladies Du Coeur Et Des Vaisseaux|November 1, 1994
New FDA guidelines on the treatment of hypertension: comparison of different therapeutic classes according to trough/peak blood pressure responsesP A Meredith
Expert Opinion on Investigational Drugs|July 5, 2005
Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivityP A Meredith
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1993
Dihydropyridines versus other agents in the treatment of hypertension in the elderly. Part 3: Safety, efficacy, tolerability and duration of actionP A Meredith
Journal of Cardiovascular Pharmacology|May 30, 1998
How to evaluate the duration of blood pressure control: the trough:peak ratio and 24-hour monitoringP A Meredith
BMJ (Clinical Research Ed.)|March 6, 1998
Enhancing patients' compliance. Electronic monitoring approaches should be more widely usedP A Meredith
The American Journal of Cardiology|August 7, 1999
Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartanP A Meredith
Blood Pressure Monitoring|July 25, 2000
Intrinsically long-acting agents compared with long-acting chronoformulationsP A Meredith
Pageof 21

Showing results (11-20 of 206) with videos related to

Sort By:
Pageof 21
Heart (British Cardiac Society)|August 24, 2000
ACE inhibition and AT(1) receptor blockers: efficacy and duration in hypertensionP A Meredith
BMJ (Clinical Research Ed.)|December 5, 1992
Patient complianceP A Meredith
American Journal of Hypertension|October 1, 1995
Organ protection and optimal blood pressure controlP A Meredith
Archives Des Maladies Du Coeur Et Des Vaisseaux|November 1, 1994
New FDA guidelines on the treatment of hypertension: comparison of different therapeutic classes according to trough/peak blood pressure responsesP A Meredith
Expert Opinion on Investigational Drugs|July 5, 2005
Lercanidipine: a novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivityP A Meredith
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|December 1, 1993
Dihydropyridines versus other agents in the treatment of hypertension in the elderly. Part 3: Safety, efficacy, tolerability and duration of actionP A Meredith
Journal of Cardiovascular Pharmacology|May 30, 1998
How to evaluate the duration of blood pressure control: the trough:peak ratio and 24-hour monitoringP A Meredith
BMJ (Clinical Research Ed.)|March 6, 1998
Enhancing patients' compliance. Electronic monitoring approaches should be more widely usedP A Meredith
The American Journal of Cardiology|August 7, 1999
Optimal dosing characteristics of the angiotensin II receptor antagonist telmisartanP A Meredith
Blood Pressure Monitoring|July 25, 2000
Intrinsically long-acting agents compared with long-acting chronoformulationsP A Meredith
Pageof 21